COX-2 FDA Advisory Committee Meeting February 16-18, 2005 Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee

Slides Presented at COX-2 Meeting

As a service to the public and the medical community, copies of the slides presented at this public meeting are provided below.

Day 1 Presentation Slides:

Byron Cryer GI Toxicity with NSAIDs

Fitzgerald Thromboxane Prostacycline talk

Merck Vioxx talk

FDA Vioxx talk

Pfizer Celebrex talk

FDA Celebrex talk

NCI APC & PreSAP Colon Polyp Studies with Celebrex

Pfizer Bextra talk

FDA Bextra talk

Bayer & Roche Naproxen talk

Day 2 Presentation Slides:

Platt Observational Studies Evaluation talk

FDA Graham Observational Studies with Coxibs talk

Merck Etoricoxib talk

FDA Etoricoxib talk

Novartis Lumiracoxib talk

FDA Luimiracoxib talk

Open Public Hearing

Day 3 Presentation Slides:

ADAPT Alzheimer's Study Celebrex & Naproxen talk

Packer Evaluation of Infrequent Events talk

Temple Future Directions for Cox-2 Inhibitors talk

FDA Labeling Restriction Strategies talk

Sponsor Two-Minute Summary talks

Questions to the Committee